Phathom Completes Enrollment for Phase 2 EoE Trial, Topline Data Expected Q4 2026
PHAT sits 40% above its 52-week low of $7.61.
Summary
Phathom Pharmaceuticals has completed enrollment of 95 patients in its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA for eosinophilic esophagitis. This follows an 8-K filed earlier today announcing the same milestone. Completing enrollment is a significant step in clinical development, de-risking the trial execution and moving the company closer to potential new indications for its drug. Topline results from this trial are anticipated in Q4 2026, which will be a key data readout for the company.
At the time of this announcement, PHAT was trading at $10.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $852.6M. The 52-week trading range was $7.61 to $18.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.